in its filing to the exchanges informed that the company has received final approval for USFDA for Valsartan and Hydrochlorothiazide Tablets in the strengths of 80 mg/12.5 mg, 160 mtg/12.5 mg, 160 mg/25 mg, 320 mtg/12.5 mg, and 320 mg/25 mg.
“The drug is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems,” the company said in a press note to the exchanges on Saturday.
It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad, the company added.
The group now has 256 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY04.
Cadila Healthcare Ltd's share price ended at Rs341, up by Rs10.65 or 3.22%, from its previous close of Rs330.35 on the BSE.
The scrip opened at Rs332 and touched a high and low of Rs349.40 and Rs329.50, respectively. A total of 40,02,595 (NSE+BSE) shares have traded on the counter. The current market cap of the company is Rs35,037.59cr.